Industry View On Biosimilar Reimbursement Draws Congressional Support
This article was originally published in The Pink Sheet Daily
A bipartisan group of US House members writes to the CMS chief urging him to publish a final Medicare payment rule "that provides each biosimilar with a unique code" rather than the proposed method of lumping all products referencing the same biologic into a single code.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.